Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model

被引:53
作者
Charman, SA
McLennan, DN
Edwards, GA
Porter, CJH
机构
[1] Monash Univ, Victorian Coll Pharm, Dept Pharmaceut, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Dept Vet Sci, Werribee, Vic 3030, Australia
关键词
insulin; subcutaneous; absorption; lymph; protein; bioavailability;
D O I
10.1023/A:1013046918190
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. This study was conducted to explore the role of the peripheral lymphatics in insulin absorption following subcutaneous (SC) administration using a sheep model that allows continuous collection of peripheral lymph and simultaneous assessment of systemic bioavailability. Methods: In a parallel group design, soluble human insulin (0.5 IU/ kg) was administered by bolus SC injection into the interdigital space of the hind leg of non-cannulated control sheep, and sheep in which the efferent popliteal lymph duct was cannulated. A separate group received a bolus IV injection (0.15 IU/kg). Blood was sampled from all animals, and lymph was collected continuously over 12 h postdosing. Samples were assayed for insulin by ELISA. Results. The SC bioavailability of insulin in control sheep was 31.5 +/- 3.2%, which was significantly higher than when the peripheral lymph was continuously collected (18.4 +/- 1.7%). In the lymph-cannulated animals, 17.3 +/- 1.0% of the dose was collected in peripheral lymph. Conclusions. Based on the direct measurement of insulin in regional lymph and on the decrease in the systemic bioavailability when rea gional lymph was continuously collected, the results demonstrate that lymphatic absorption contributed significantly to the overall insulin bioavailability following SC administration to sheep.
引用
收藏
页码:1620 / 1626
页数:7
相关论文
共 32 条
  • [1] Anderson JH, 1998, DRUG TODAY, V34, P37
  • [2] INTERSTITIAL-LYMPHATIC MECHANISMS IN THE CONTROL OF EXTRACELLULAR FLUID VOLUME
    AUKLAND, K
    REED, RK
    [J]. PHYSIOLOGICAL REVIEWS, 1993, 73 (01) : 1 - 78
  • [3] ABSORPTION KINETICS AND BIOLOGIC EFFECTS OF SUBCUTANEOUSLY INJECTED INSULIN PREPARATIONS
    BERGER, M
    CUPPERS, HJ
    HEGNER, H
    JORGENS, V
    BERCHTOLD, P
    [J]. DIABETES CARE, 1982, 5 (02) : 77 - 91
  • [4] ABSORPTION KINETICS OF SUBCUTANEOUSLY INJECTED INSULIN - EVIDENCE FOR DEGRADATION AT THE INJECTION SITE
    BERGER, M
    HALBAN, PA
    GIRARDIER, L
    SEYDOUX, J
    OFFORD, RE
    RENOLD, AE
    [J]. DIABETOLOGIA, 1979, 17 (02) : 97 - 99
  • [5] BINDER C, 1983, ARTIFICIAL SYSTEMS I, P53
  • [6] BINDER C, 1969, ACTA PHARM TOXICOL S, V2, P1
  • [7] BRANGE J, 1992, HORM METAB RES, V26, P125
  • [8] MONOMERIC INSULINS OBTAINED BY PROTEIN ENGINEERING AND THEIR MEDICAL IMPLICATIONS
    BRANGE, J
    RIBEL, U
    HANSEN, JF
    DODSON, G
    HANSEN, MT
    HAVELUND, S
    MELBERG, SG
    NORRIS, F
    NORRIS, K
    SNEL, L
    SORENSEN, AR
    VOIGT, HO
    [J]. NATURE, 1988, 333 (6174) : 679 - 682
  • [9] MONOMERIC INSULINS AND THEIR EXPERIMENTAL AND CLINICAL IMPLICATIONS
    BRANGE, J
    OWENS, DR
    KANG, S
    VOLUND, A
    [J]. DIABETES CARE, 1990, 13 (09) : 923 - 954
  • [10] Charman SA, 2000, J PHARM SCI, V89, P168, DOI 10.1002/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.3.CO